PHD2/prolylhydroxylase抗体;PHD2/prolylhydroxylase Antibody—艾普蒂 新品

+ +

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     Western blot analysis of PHD2 / prolyl hydroxylase expression in SH-SY5Y cell lysate.    

  
  

Prolyl hydroxylase domain-containing protein 2 (PHD2), also known as EGLN1. is a critical oxygen-sensing enzyme belonging to the prolyl hydroxylase family. It plays a central role in cellular adaptation to hypoxia by regulating the stability of hypoxia-inducible factor alpha (HIF-α). Under normoxic conditions, PHD2 hydroxylates specific proline residues on HIF-α subunits, marking them for proteasomal degradation via the von Hippel-Lindau (VHL) ubiquitin ligase complex. This process is oxygen-dependent, as PHD2 requires molecular oxygen, iron, and 2-oxoglutarate as cofactors. During hypoxia, PHD2 activity decreases, allowing HIF-α to accumulate, dimerize with HIF-β, and activate genes involved in angiogenesis, erythropoiesis, and metabolism.

Antibodies against PHD2 are essential tools for studying its expression, localization, and function in physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate PHD2's role in diseases such as cancer, ischemic disorders, and chronic kidney disease. Research has highlighted PHD2 as a potential therapeutic target, with inhibitors explored for treating anemia and ischemic conditions. Specific PHD2 antibodies help differentiate its activity from related isoforms (PHD1/PHD3) and assess tissue-specific regulation of hypoxia pathways. Validating these antibodies for selectivity and cross-reactivity remains crucial for accurate interpretation of experimental data in hypoxia-related studies.